Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Kai Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-7362-3094; OpenAlex author ID A5069601968, A5108141368, A5129433712. Sources: ClinicalTrials.gov.

Their work

Papers
19 (first author 3, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2019: 1 paper, 1 trial · 2020: none · 2021: 2 papers · 2022: 5 papers · 2023: 5 papers · 2024: none · 2025: 3 papers · 2026: 3 papers

Papers 19

  1. 3D epigenomic remodelling mediated by Foxa1 drives gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2026.218721↗
  2. LINC01137 facilitates pancreatic cancer stemness, chemoresistance and proliferation via the miR-7155-5p/KLF12/PI3K-Akt axis. First author DOI 10.1016/j.ijbiomac.2026.150088↗
  3. SEC14L2 contributes to tumor progression by enhancing USP5-driven RBM3 deubiquitination in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41388-026-03968-6↗
  4. Neobractatin and Trametinib Synergistically Induce Apoptosis and Gasdermin E-Dependent Pyroptosis in Pancreatic Cancer Cells. Co-author DOI 10.1002/mco2.70250↗
  5. Single-atom aptamer anchoring enables light-addressable multiplexed biosensing for early detection of pancreatic cancer. Last author DOI 10.1016/j.bios.2025.117792↗
  6. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Co-author DOI 10.1038/s41418-024-01423-1↗
  7. Multiplex Digital Polymerase Chain Reaction on a Droplet Array SlipChip for Analysis of KRAS Mutations in Pancreatic Cancer. Co-author DOI 10.1021/acssensors.2c01776↗
  8. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04742-y↗
  9. Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-023-01506-5↗
  10. Retraction Note: LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Co-author DOI 10.1186/s13578-023-01103-6↗
  11. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  12. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant … First author DOI 10.1002/cam4.4698↗
  13. Robotic versus open pancreaticoduodenectomy with vascular resection for pancreatic ductal adenocarcinoma: surgical and oncological outcomes from pilot experien… Co-author DOI 10.1007/s00423-021-02364-w↗
  14. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-022-01338-9↗
  15. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  16. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗
  17. Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients. Co-author DOI 10.1186/s12885-021-09056-0↗
  18. LncRNA SNHG7 Regulates Mesenchymal Stem Cell Through the Notch1/Jagged1/Hes-1 Signaling Pathway and Influences Folfirinox Resistance in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.719855↗
  19. LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Co-author DOI 10.1186/s13578-019-0290-2↗

Trials 1

  1. Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer Principal investigator NCT04211948↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zengyu Feng · 7 shared papers, 2022–2026 · strength 1.24
  2. Baiyong Shen · 6 shared papers, 2021–2025 · strength 0.98
  3. Jiabin Jin · 5 shared papers, 2021–2025 · strength 0.89
  4. Chenghong Peng · 6 shared papers, 2022–2023 · strength 0.85
  5. Yizhi Cao · 5 shared papers, 2022–2026 · strength 0.83
  6. Kexian Li · 5 shared papers, 2022–2023 · strength 0.70
  7. Xiaxing Deng · 4 shared papers, 2021–2023 · strength 0.64
  8. Dongfeng Cheng · 4 shared papers, 2019–2023 · strength 0.62
  9. Jiewei Lin · 4 shared papers, 2022–2025 · strength 0.59
  10. Lingxi Jiang · 4 shared papers, 2022–2023 · strength 0.55
  11. Yu Jiang · 3 shared papers, 2021–2023 · strength 0.50
  12. Ningzhen Fu · 3 shared papers, 2021–2023 · strength 0.50
  13. Jingrui Yang · 3 shared papers, 2019–2023 · strength 0.45
  14. Hao Chen · 3 shared papers, 2022–2023 · strength 0.45
  15. Hao Chen · 3 shared papers, 2021–2022 · strength 0.41
  16. Yiran Zhou · 3 shared papers, 2019–2023 · strength 0.41
  17. Lijie Han · 3 shared papers, 2022–2023 · strength 0.41
  18. Yongsheng Jiang · 3 shared papers, 2022–2023 · strength 0.41
  19. Jiancheng Wang · 2 shared papers, 2022–2025 · strength 0.31
  20. Hongxia Xu · 1 shared paper, 2026 · strength 0.29
  21. Chenghong Peng · 1 shared paper, 2026 · strength 0.29
  22. Jiancheng Wang · 2 shared papers, 2022–2023 · strength 0.28
  23. Jiaxin Luo · 2 shared papers, 2022–2023 · strength 0.28
  24. Xuelong Wang · 1 shared paper, 2026 · strength 0.27
  25. Jiabin Jin · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.